November 2, 2011 - A new FDA adverse events study entitled "Suicidal Behavior and Depression in Smoking Cessation Treatments" identified "3,249 reported cases of suicidal/self-injurious behavior or depression, 2,925 (90%) for varenicline, 229 (7%) for bupropion, and 95 (3%) for nicotine replacement." It concluded that, "The findings for varenicline, combined with other problems with its safety profile, render it unsuitable for first-line use in smoking cessation." November 24, 2011 - The FDA issues a "Safety Announcement" that although new hospitalization study of risk of neuropsychiatric adverse events found no difference between Chantix and NRT, that the study does "not rule out an increased risk of other neuropsychiatric events with Chantix." For example, obviously, a person successful at suicide is not normally hospitalized
It keeps me awake and focused for hours. The wintergreen flavor is my favorite
These platforms allow you to learn from others' experiences and even share your own
This gum must be chewed according to the labeled instructions to be effective
I found a knife and cut off a small sliver of tobacco
